zonisamide has been researched along with Body Weight in 12 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adjunctive zonisamide was associated with beneficial effects on mood and body weight in some patients with bipolar disorders, but was also associated with a high discontinuation rate due to worsening mood symptoms." | 9.11 | Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. ( Altshuler, LL; Black, D; Frye, MA; Grunze, H; Keck, PE; Kupka, RW; Leverich, GS; McElroy, SL; Nolen, WA; Post, RM; Suppes, T; Walden, J, 2005) |
| "To investigate the impact of zonisamide (ZNS) on body weight in patients with epilepsy." | 7.75 | The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy. ( Bauer, J; Wellmer, J; Wellmer, S, 2009) |
| " Zonisamide inhibits carbonic anhydrase, and induces weight loss in obese patients." | 5.19 | Zonisamide reduces obstructive sleep apnoea: a randomised placebo-controlled study. ( Eskandari, D; Grote, L; Hedner, J; Karimi, M; Stenlöf, K; Zou, D, 2014) |
| "Adjunctive zonisamide was associated with beneficial effects on mood and body weight in some patients with bipolar disorders, but was also associated with a high discontinuation rate due to worsening mood symptoms." | 5.11 | Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. ( Altshuler, LL; Black, D; Frye, MA; Grunze, H; Keck, PE; Kupka, RW; Leverich, GS; McElroy, SL; Nolen, WA; Post, RM; Suppes, T; Walden, J, 2005) |
| "These data collectively show an impact of olanzapine on body weight and lipid metabolism, which is ameliorated by co-administration with zonisamide." | 3.85 | Prevention of the adverse effects of olanzapine on lipid metabolism with the antiepileptic zonisamide. ( Cowley, MA; Oldfield, BJ; Stefanidis, A; Watt, MJ, 2017) |
| "To investigate the impact of zonisamide (ZNS) on body weight in patients with epilepsy." | 3.75 | The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy. ( Bauer, J; Wellmer, J; Wellmer, S, 2009) |
| "Zonisamide is a novel antiepileptic drug associated with weight loss." | 2.71 | Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. ( Hudson, JI; Keck, PE; Kotwal, R; McElroy, SL; Nelson, EB, 2004) |
| " The pharmacokinetics of the 282 ZNS concentrations at a steady state obtained from 99 Japanese epileptic patients was performed with a nonlinear mixed-effect modeling program, using a one-compartment open pharmacokinetic model with first-order elimination." | 1.35 | Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance. ( Hashimoto, N; Higa, Y; Ishitsu, T; Nakagawa, K; Okada, Y; Seo, T; Wanibuchi, A, 2008) |
| "Zonisamide was relatively well tolerated during the study." | 1.27 | Chronic toxicity of the anticonvulsant zonisamide in beagle dogs. ( Barsoum, NJ; DiFonzo, CJ; Macallum, GE; Smith, GS; Walker, RM, 1988) |
| "Zonisamide (CI-912) is an experimental antiepileptic drug." | 1.27 | Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. ( Buchanan, RA; Friel, PN; Levy, RH; McLean, JR; Ojemann, LM; Shastri, RA; Wilensky, AJ, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Tian, JH | 1 |
| Wu, Q | 1 |
| He, YX | 1 |
| Shen, QY | 1 |
| Rekep, M | 1 |
| Zhang, GP | 1 |
| Luo, JD | 1 |
| Xue, Q | 1 |
| Liu, YH | 1 |
| Stefanidis, A | 1 |
| Watt, MJ | 1 |
| Cowley, MA | 2 |
| Oldfield, BJ | 1 |
| Eskandari, D | 1 |
| Zou, D | 1 |
| Karimi, M | 1 |
| Stenlöf, K | 1 |
| Grote, L | 1 |
| Hedner, J | 1 |
| Okada, Y | 1 |
| Seo, T | 1 |
| Ishitsu, T | 1 |
| Wanibuchi, A | 1 |
| Hashimoto, N | 1 |
| Higa, Y | 1 |
| Nakagawa, K | 1 |
| Wellmer, J | 1 |
| Wellmer, S | 1 |
| Bauer, J | 1 |
| McElroy, SL | 2 |
| Kotwal, R | 1 |
| Hudson, JI | 1 |
| Nelson, EB | 1 |
| Keck, PE | 2 |
| Suppes, T | 1 |
| Black, D | 1 |
| Frye, MA | 1 |
| Altshuler, LL | 1 |
| Nolen, WA | 1 |
| Kupka, RW | 1 |
| Leverich, GS | 1 |
| Walden, J | 1 |
| Grunze, H | 1 |
| Post, RM | 1 |
| Wallingford, NM | 1 |
| Sinnayah, P | 1 |
| Bymaster, FP | 1 |
| Gadde, KM | 1 |
| Krishnan, RK | 1 |
| McKinney, AA | 1 |
| Landbloom, RP | 1 |
| Tollefson, GD | 1 |
| Walker, RM | 1 |
| DiFonzo, CJ | 1 |
| Barsoum, NJ | 1 |
| Smith, GS | 1 |
| Macallum, GE | 1 |
| Ojemann, LM | 1 |
| Shastri, RA | 1 |
| Wilensky, AJ | 1 |
| Friel, PN | 1 |
| Levy, RH | 1 |
| McLean, JR | 1 |
| Buchanan, RA | 1 |
3 trials available for zonisamide and Body Weight
| Article | Year |
|---|---|
Zonisamide reduces obstructive sleep apnoea: a randomised placebo-controlled study.
Topics: Aged; Anthropometry; Body Mass Index; Body Weight; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase | 2014 |
Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial.
Topics: Administration, Oral; Adult; Anticonvulsants; Body Weight; Bulimia; Female; Humans; Isoxazoles; Male | 2004 |
Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial.
Topics: Adult; Ambulatory Care; Anticonvulsants; Bipolar Disorder; Body Mass Index; Body Weight; Drug Therap | 2005 |
9 other studies available for zonisamide and Body Weight
| Article | Year |
|---|---|
Zonisamide, an antiepileptic drug, alleviates diabetic cardiomyopathy by inhibiting endoplasmic reticulum stress.
Topics: Animals; Anticonvulsants; Apoptosis; Blood Glucose; Body Weight; Cardiomegaly; Diabetes Mellitus, Ty | 2021 |
Prevention of the adverse effects of olanzapine on lipid metabolism with the antiepileptic zonisamide.
Topics: Adiposity; Animals; Antioxidants; Antipsychotic Agents; Benzodiazepines; Body Weight; Drug Therapy, | 2017 |
Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance.
Topics: Adolescent; Adult; Algorithms; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Body Weight; Child; C | 2008 |
The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Body Mass Index; Body Weight; Dose-Response Relationship, | 2009 |
[Effective and 15 years experience. New add-on option in epilepsy therapy]].
Topics: Anticonvulsants; Body Weight; Child; Controlled Clinical Trials as Topic; Dose-Response Relationship | 2005 |
[Control of side effects. Add on therapy demonstrates good tolerance].
Topics: Anticonvulsants; Body Weight; Controlled Clinical Trials as Topic; Drug Interactions; Drug Therapy, | 2005 |
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.
Topics: Animals; Anticonvulsants; Appetite Regulation; Benzodiazepines; Biomarkers; Body Weight; Diabetes Me | 2008 |
Chronic toxicity of the anticonvulsant zonisamide in beagle dogs.
Topics: Administration, Oral; Animals; Anticonvulsants; Body Weight; Dogs; Eating; Electrocardiography; Isox | 1988 |
Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy.
Topics: Adolescent; Adult; Anticonvulsants; Body Weight; Carbamazepine; Drug Therapy, Combination; Epilepsy; | 1986 |